{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:42:17Z","timestamp":1781840537313,"version":"3.54.5"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[1996,2,1]],"date-time":"1996-02-01T00:00:00Z","timestamp":823132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1996,2]]},"abstract":"<jats:p>Agar dilution was used to determine the MICs of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents for 203 penicillin-susceptible and -resistant pneumococci. All pneumococci were inhibited by RPR 106972 at &lt; or = 0.5 microgram\/ml. Cefditoren was very active against all pneumococcal groups, with MICs of &lt; or = 2.0 micrograms\/ml. Amoxicillin with or without clavulanate was the next most active oral beta-lactam, followed by cefdinir, cefuroxime, cefpodoxime, and cefprozil. U-100592 and U-100766 were very active against all classes of pneumococci, with all MICs &lt; or = 1.0 microgram\/ml.<\/jats:p>","DOI":"10.1128\/aac.40.2.481","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:24:50Z","timestamp":1539044690000},"page":"481-484","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":66,"title":["Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci"],"prefix":"10.1128","volume":"40","author":[{"given":"S K","family":"Spangler","sequence":"first","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P C","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.40.2.481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.40.2.481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:04:59Z","timestamp":1645473899000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.40.2.481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,2]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1996,2]]}},"alternative-id":["10.1128\/AAC.40.2.481"],"URL":"https:\/\/doi.org\/10.1128\/aac.40.2.481","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,2]]},"assertion":[{"value":"1996-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}